Nuveen
SNDX icon

Nuveen’s Syndax Pharmaceuticals SNDX Stock Holding History

Nuveen’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.8M Sell
1,364,575
-130,070
-9% -$2.7M 0.01% 1008
2026
Q1 		$34.9M Buy
1,494,645
+11,643
+0.8% +$253K 0.01% 817
2025
Q4 		$31.2M Buy
1,483,002
+7,204
+0.5% +$126K 0.01% 882
2025
Q3 		$22.7M Buy
1,475,798
+1,209,755
+455% +$15.8M 0.01% 1069
2025
Q2 		$2.49M Buy
266,043
+41,890
+19% +$461K ﹤0.01% 2208
2025
Q1 		$2.75M Sell
224,153
-209,905
-48% -$2.96M ﹤0.01% 2194
2024
Q4 		$5.74M Sell
434,058
-25,474
-6% -$436K ﹤0.01% 1920
2024
Q3 		$8.85M Sell
459,532
-96,882
-17% -$2M ﹤0.01% 1688
2024
Q2 		$11.4M Buy
556,414
+163,728
+42% +$3.43M ﹤0.01% 1501
2024
Q1 		$9.35M Sell
392,686
-231,324
-37% -$5.16M ﹤0.01% 1636
2023
Q4 		$13.5M Buy
624,010
+450,571
+260% +$6.93M ﹤0.01% 1396
2023
Q3 		$2.52M Buy
173,439
+12,492
+8% +$236K ﹤0.01% 2207
2023
Q2 		$3.37M Buy
160,947
+9,710
+6% +$202K ﹤0.01% 2105
2023
Q1 		$3.19M Buy
151,237
+6,375
+4% +$159K ﹤0.01% 2131
2022
Q4 		$3.69M Sell
144,862
-21,015
-13% -$490K ﹤0.01% 2087
2022
Q3 		$3.99M Buy
165,877
+35
+0% +$785 ﹤0.01% 2030
2022
Q2 		$3.19M Buy
165,842
+2,252
+1% +$37.5K ﹤0.01% 2195
2022
Q1 		$2.77M Sell
163,590
-271
-0.2% -$4.56K ﹤0.01% 2364
2021
Q4 		$2.93M Sell
163,861
-10,809
-6% -$200K ﹤0.01% 2379
2021
Q3 		$3.46M Sell
174,670
-42,244
-19% -$704K ﹤0.01% 2415
2021
Q2 		$3.73M Buy
216,914
+78,723
+57% +$1.44M ﹤0.01% 2396
2021
Q1 		$3.09M Sell
138,191
-18,147
-12% -$410K ﹤0.01% 2407
2020
Q4 		$3.48M Sell
156,338
-30,303
-16% -$628K ﹤0.01% 2250
2020
Q3 		$2.75M Buy
186,641
+69,338
+59% +$1.06M ﹤0.01% 2223
2020
Q2 		$1.74M Buy
117,303
+42,266
+56% +$644K ﹤0.01% 2400
2020
Q1 		$824K Sell
75,037
-14,119
-16% -$133K ﹤0.01% 2598
2019
Q4 		$783K Sell
89,156
-59,832
-40% -$439K ﹤0.01% 2773
2019
Q3 		$1.11M Buy
148,988
+39,756
+36% +$362K ﹤0.01% 2656
2019
Q2 		$1.02M Buy
+109,232
New +$796K ﹤0.01% 2731

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Nuveen's SNDX Position: Q2 2026 in Review

Nuveen reduced its Syndax Pharmaceuticals (SNDX) stake by 8.7% in Q2 2026, selling an estimated $2.7M and leaving 1,364,575 shares worth $29.8M. The position accounts for 0.01% of the portfolio, ranked #1008.

Nuveen first reported a position in SNDX in Q2 2019 and has held it in 29 quarters since. The position peaked at $34.9M in Q1 2026. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Nuveen held 1,364,575 shares of Syndax Pharmaceuticals worth $29.8M as of Q2 2026.
  • Nuveen sold 130,070 Syndax Pharmaceuticals shares in Q2 2026, an estimated $2.7M.
  • Syndax Pharmaceuticals made up 0.01% of Nuveen's portfolio in Q2 2026, its #1008 holding.
  • Nuveen first reported a position in Syndax Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Syndax Pharmaceuticals position peaked at $34.9M in Q1 2026.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.